For example, a recent phase 1 clinical trial investigating a single dose of [177Lu]Lu-PSMA-617 followed by maintenance pembrolizumab in metastatic castration-resistant prostate cancer demonstrated that this sequence was safe and feasible, with preliminary signs of anti-tumour efficacy [8]. Here, FOLH1 is linked to neoplasm.